Figure 2From: Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) Overall survival, Kaplan-Meier survival estimate. A, c.35 G > A KRAS mutant patients versus other KRAS mutant patients; B, other KRAS mutant patients versus KRAS wild-type patients.Back to article page